Market revenue in 2023 | USD 45.1 million |
Market revenue in 2030 | USD 59.7 million |
Growth rate | 4.1% (CAGR from 2023 to 2030) |
Largest segment | Coronary stents |
Fastest growing segment | Accessory Devices |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Intravascular Imaging Catheters and Pressure Guidewires, Coronary Stents, PTCA Balloon Catheters, Accessory Devices |
Key market players worldwide | Abbott Laboratories, Medtronic PLC, Boston Scientific Corp, Koninklijke Philips NV, Cardinal Health Inc, Terumo Corp, Teleflex Inc, B. Braun, Biosensors, BIOTRONIK, Asahi Intecc Co Ltd, Cook Medical, Merit Medical Systems Inc, Haemonetics Corp, Vascular Solutions, Zeon Corp, Alvimedica, Meril Life, Medinol |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to interventional cardiology devices market will help companies and investors design strategic landscapes.
Coronary stents was the largest segment with a revenue share of 49.89% in 2023. Horizon Databook has segmented the Saudi Arabia interventional cardiology devices market based on intravascular imaging catheters and pressure guidewires, coronary stents, ptca balloon catheters, accessory devices covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing healthcare expenditure with growing number of hospitals and rising target population across the country is expected to contribute to market growth. For instance, in September 2023, an article by Cardiac Interventions highlighted a review of TARGET IV trial for Firehawk rapamycin-eluting coronary stent made from cobalt chromium.
The first three trials have shown promising results among patient populations across 40 countries, including Saudi Arabia. According to a recent article released by Saudi Food and Drug Authority (SFDA), the Paclitaxel eluting stent and Paclitaxel coated balloon products were examined in a postmarket evaluation in Saudi Arabia by international regulatory offices and specialized societies.
Moreover, the SFDA took the initiative to evaluate the safety of Paclitaxel eluting stent and Paclitaxel coated balloon with reference to recent accumulated clinical data, which revealed that they carry the risk of long-term mortality. However, more studies are required when it is compared to noncoated devices.
Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia interventional cardiology devices market , including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia interventional cardiology devices market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account